G**********n
发帖数: 973 | 1 NEW YORK, Feb 13 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research)
said on Tuesday its HIV treatment maraviroc will receive an accelerated
review from regulators in the United States and Europe.
If approved by the regulatory agencies, maraviroc would be the first in a
new class of HIV/AIDS treatments called CCR5 antagonists that work by
blocking viral entry, the drug maker said.
Most existing HIV drugs work inside the body's immune cells, after the virus
has infected a patient. Rather th | R*j
发帖数: 248 | 2 很好啊。cocktail里又多了一味。
anti-HIV药价格普遍非常高(其实抗病毒的药都贵）。而得AIDS的人大都是穷人， 这个
药估计不会boost Pfizer的revenue.
virus
,
entering
【在 G**********n 的大作中提到】
: NEW YORK, Feb 13 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research)
: said on Tuesday its HIV treatment maraviroc will receive an accelerated
: review from regulators in the United States and Europe.
: If approved by the regulatory agencies, maraviroc would be the first in a
: new class of HIV/AIDS treatments called CCR5 antagonists that work by
: blocking viral entry, the drug maker said.
: Most existing HIV drugs work inside the body's immune cells, after the virus
: has infected a patient. Rather th
| G**********n
发帖数: 973 | 3 Pfizer, based in New York, learned this week that maraviroc will receive
accelerated review and, along with Merck's MK-0518, may be cleared for U.S.
sale this year. The two drugs will enter an estimated $5.9 billion market,
according to Wolters Kluwer Health, which gathers data on the industry.
2008 Sales
Once approved, maraviroc may generate $145 million in 2008, and Merck's new
drug may raise about $50 million, said Barbara Ryan, a Deutsche Bank analyst
. The therapies may cost users about $5, |
|
